KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Cash & Equivalents (2016 - 2026)

Medtronic's Cash & Equivalents history spans 14 years, with the latest figure at $1.1 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 7.5% to $1.1 billion in Q1 2026 year-over-year; TTM through Jan 2026 was $1.1 billion, a 7.5% decrease, with the full-year FY2025 number at $2.2 billion, up 72.74% from a year prior.
  • Cash & Equivalents hit $1.1 billion in Q1 2026 for Medtronic, down from $1.3 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for MDT hit a ceiling of $4.8 billion in Q4 2022 and a floor of $1.1 billion in Q1 2026.
  • Historically, Cash & Equivalents has averaged $2.1 billion across 5 years, with a median of $1.4 billion in 2024.
  • Biggest five-year swings in Cash & Equivalents: plummeted 72.85% in 2023 and later soared 72.74% in 2025.
  • Tracing MDT's Cash & Equivalents over 5 years: stood at $4.8 billion in 2022, then plummeted by 72.85% to $1.3 billion in 2023, then rose by 6.33% to $1.4 billion in 2024, then decreased by 8.03% to $1.3 billion in 2025, then fell by 10.53% to $1.1 billion in 2026.
  • Business Quant data shows Cash & Equivalents for MDT at $1.1 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.